Skip to main content

Our Outputs

Some of our recent papers.

Meijer AJM, Diepstraten FA, Ansari M, Bouffet E, Bleyer A, Fresneau B, Geller JI, Huitema ADR, Kogner P, Maibach R, O'Neill AF, Papadakis V, Rajput KM, Veal GJ, Sullivan M, van den Heuvel-Eibrink MM, Brock PR. The use of sodium thiosulfate as an otoprotectant in cancer patients treated with platinum compounds: a review of the literatureJournal of Clinical Oncology 2024, 42(18), 2219-2232.

Spiliopoulou P, Kazmi F, Aroldi F, Holmes T, Thompson D, Griffiths L, Qi C, Parkes M, Lord S, Veal GJ, Harrison DJ, Coyle VM, Graham J, Evans TRJ, Blagden SP. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)Journal of Experimental and Clinical Cancer Research 2024, 43(1), 100.

Bell HL, Blair HJ, Jepson Gosling SJ, Galler M, Astley D, Moorman AV, Heidenreich O, Veal GJ, van Delft FW, Lunec J, Irving JAE. Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemiaLeukemia 2024, 38, 1223-1235.

Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Miller R, Veal GJ, Corrigan CJ, Till SJ, Figini M, Canevari S, Barton C, Jones P, Mellor S, Carroll S, Selkirk C, Nintos G, Kwatra V, Funingana I-G, Doherty G, Gould HJ, Pellizzari G, Nakamura M, Ilieva KM, Khiabany A, Stavraka C, Chauhan J, Gillett C, Pinder S, Bax HJ, Josephs DH, Karagiannis SN. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trialNature Communications 2023, 14(1), 4180.

Barnett S, Makin G, Tweddle DA, Osborne C, Veal GJ. Generation of evidence-based carboplatin dosing guidelines for neonates and infantsBritish Journal of Cancer 2023, 129, 1773–1779.

Damoiseaux D, Amant F, Beijnen JH, Barnett S, Veal GJ, Huitema ADR, Dorlo TPC. Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milkCPT: Pharmacometrics and Systems Pharmacology 2023, 12(12), 1931-1944.

Barnett S, Nyein AC, Galler M, Jamieson D, Davies M, Connor P, Veal GJ. Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case reportCancer Chemotherapy and Pharmacology 2023, 92, 325–328.

Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, Dragoni I, Heinzmann K, Potter S, Salisbury BM, Chenard-Poirier M, Greystoke A, Howell EC, Innes WA, Morris K, Plummer C, Rata M, Petrides G, Keun HC, Banerji U, Plummer R. A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancerClinical Cancer Research 2023, 29(8), 1429-1439.

Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D, Fernandez-Garcia P, Lladó V, McNicholl A, Roselló C, Taylor R, Azaro A, Ahnert JR, Sludden J, Veal G, Plummer R, Urruticoechea A, Lahuerta A, Mujika K, Escriba P. A Phase 1/2A trial of idroxioleic acid: First-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory gliomaBritish Journal of Cancer 2023, 129, 811-818.

Kristeleit R, Plummer R, Jones R, Carter L, Blagden S, Sarker D, Arkenau T, Evans TRJ, Danson S, Symeonides SN, Veal GJ, Klencke BJ, Kowalski MM, Banerji U. A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerBritish Journal of Cancer 2023, 129, 38-45.

Geurten C, Errington J, Barnett S, Patel H, Noor S, Saraff V, Veal GJ, Gatz SA. Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastomaPediatric Blood and Cancer 2023, 70(9), e30430.

Rahman R, Janowski M, Killick-Cole CL, Singleton WGB, Campbell E, Walczak P, Khatua S, Faltings L, Symons M, Schneider JR, Kwan K, Boockvar JA, Gill SS, Oliveira JM, Beccaria K, Carpentier A, Canney M, Pearl M, Veal GJ, Meijer L, Walker DA. Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical TrialsCancers 2023, 15(3), 857.

Barnett S, Hellman F, Parke E, Makin G, Tweddle DA, Osborne C, Hempel G, Veal GJ. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patientsEuropean Journal of Cancer 2022, 164, 127-136.

Nijstad AL, Barnett S, Lalmohamed A, Bérénos IM, Parke E, Carruthers V, Tweddle DA, Kong J, Zwaan CM, Huitema ADR, Veal GJ. Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidanceEuropean Journal of Cancer 2022, 164, 137-154.

Idowu OS, Craigen JL, Veal GJ, Jamieson D. Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum. Bioanalysis 2022, 14, 1241-1249.

Carruthers V, Barnett S, Rees R, Arif T, Slater O, Ramanujachar R, Johnson K, Brown S, Graham C, Burke GAA, Veal GJ. Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case seriesPediatric Blood and Cancer 2022, 69(7), e29722.

Barnett S, Holden V, Campbell-Hewson Q, Veal GJ. Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populationsFrontiers in Oncology 2022, 11, 815040.

Apps JR, Maycock S, Ellison DW, Jaspan T, Ritzmann TA, Macarthur D, Malluci C, Wheatley K, Veal GJ, Grundy RG, Picton S. Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04)Neuro-Oncology Advances 2022, 4, 1-11.

Nijstad AL, Chu W-Y, de Vos-Kerkhof E, Enters-Weijnen CF, van de Velde ME, Kaspers GJL, Barnett S, Veal GJ, Lalmohamed A, Zwaan CM, Huitema ADR. A population pharmacokinetic modelling approach to unravel the complex pharmacokinetics of vincristine in childrenPharmaceutical Research 2022, 39, 2487-2495.

Menne T, Slade D, Savage J, Johnson S, Irving J, Kearns P, Plummer R, Shenton G, Veal GJ, Vormoor B, Vormoor J, Billingham L. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trialBMJ Open 2022, 12, e059872.

Veal GJ, Tweddle DA, Visser J, Errington J, Buck H, Marange J, Moss J, Joseph S, Mulla H. Pharmacokinetics and safety of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma: A randomized crossover clinical trialCancers 2021, 13(8), 1868.

Barnett S, Kong J, Makin G, Veal GJ. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United KingdomBritish Journal of Clinical Pharmacology 2021, 87(2), 256-262.

Gowland C, Berry P, Errington J, Jeffrey P, Bennett G, Godfrey L, Pittman M, Niewiarowski A, Symeonides SN, Veal GJ. Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I studyBioanalysis 2021, 13(2), 101-113.

Gionfriddo I, Brunetti B, Mezzasoma F, Milano F, Cardinali V, Ranieri R, Venanzi A, Pierangeli S, Vetro C, Spinozzi G, Dorillo E, Wu H, Ciurnelli R, Griffin MJ, Jennings CE, Tiavvi E, Sportoletti E, Falzetti F, de The H, Veal GJ, Martelli MP, Falini B. Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated acute myeloid leukemiaLeukemia 2021, 35, 2552–2562.

Barnett S, Errington J, Sludden J, Jamieson D, Poinsignon V, Paci A, Veal GJ. Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient populationPharmaceuticals 2021, 14(3), 272.

Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020 583:807-812.

Faivre-Finn C, Brown S, Ryan A, Greystoke A; CONCORDE Investigators. The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362. doi: 10.1016/j.clon.2020.02.003. Epub 2020 Feb 24. PMID: 32107107.

Roberts, E, Mogg, JAW, Barnfield, M, Veal, GJ. Investigating current practices in renal function measurement and carboplatin dosing in children with cancer – a UK perspective. Ped Hem Oncol 2020 37: 235-244

Merugu S, Chen L, Gavens E, Gabra H, Brougham M, Makin G, Ng A, Murphy D, Gabriel AS, Robinson ML, Wright JH, Burchill SA, Humphreys A, Bown N, Jamieson D, Tweddle DA. Detection of circulating and disseminated neuroblastoma cells using the Imagestream Imaging Flow Cytometer for use as predictive and pharmacodynamic biomarkers. Clinical Cancer Research 2020 26:122-134

Doan M, Case M, Masic D, Hennig H, McQuin C, Caicedo J, Singh S, Goodman A, Wolkenhauer O, Summers HD, Jamieson D, van Delft FW, Filby A, Carpenter AE, Rees P, Irving J. Label‐Free Leukemia Monitoring by Computer Vision. Cytometry A 2020 97:407-414

Hellmann F, Völler S, Krischke M. Jamieson D, Andre N, Bisogno G, Boddy A, Hemple G. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the “European Paediatric Oncology Off-patents Medicines Consortium” (EPOC) Trial. Eur J Drug Metab Pharmacokinet 2020 45:413–422

Yogev, O, Almeida, GS, Barker, KT, George, SL, Kwok, C, Campbell, J, Zarowiecki, M, Kleftogiannis, D, Smith, LM, Hallsworth, A, Berry, P, Möcklinghoff, T, Webber, HT, Danielson, LS, Buttery, B, Calton, EA, da Costa, BM, Jamin, Y, Lise, S, Veal, GJ, Sebire, N, Robinson, SP, Anderson, J, Chesler, L. In vivo modelling of chemo-resistant neuroblastoma provides new insights into chemo-refractory disease and metastasis. Cancer Res 2019 79: 5382-5393

Jackson, RK, Liebich, M, Berry, P, Errington, J, Liu, J, Parker, C, Moppett, J, Samarasinghe, S, Hough, R, Rowntree, C, Goulden, NJ, Vora, A, Kearns, PR, Saha, V, Hempel, G, Irving, JAE, Veal, GJ. Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia – a report from the UKALL 2011 trial. Eur J Cancer 2019 120: 75-85

Smith, SJ, Tyler, BM, Gould, T, Veal, GJ, Gorelick, N, Rowlinson, J, Serra, R, Ritchie, A, Berry, P, Otto, A, Choi, J, Skuli, N, Estevez-Cebrero, M, Shakesheff, KM, Brem, H, Grundy, RG, Rahman, R. Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste. Clin Cancer Res 2019 25: 5094-5106

Hawley, J, Veal, GJ, Errington, J, McDonald, LG, Tweddle, DA. The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma associated spinal cord compression. Ped Blood Cancer 2019 e27825 1-3

Uitrakul, S, Hutton, C, Veal, GJ, Jamieson, D. A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells. Eur J Clin Invest 2019 49: e13115 1-7

Lee, CM, Zane, NR, Veal, G, Thakker, DR. Physiologically-based pharmacokinetic models for adults and children reveal a role of intracellular tubulin binding in vincristine disposition. CPT Pharmacometrics Syst Pharmacol 2019 8: 759-768

Veal, GJ, Amankwatia, EB, Paludetto, M-N, Möcklinghoff, T, Thomson, F, André, N, Ciccolini, J, Chatelut, E. Pharmacodynamic therapeutic drug monitoring for cancer: challenges, advances and future opportunities. Ther Drug Monit 2019 41: 142-159

Adamson, PC, Veal, GJ, Womer, RB, Meany, HJ, Bernhardt, MB, Frazier, AL, Balis, FM. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear medicine based estimates of renal function. Ped Blood Cancer 2019 66: e27672 1-8

Matheson, EC, Thomas, H, Case, M, Blair, H, Jackson, RK, Masic, D, Veal, G, Halsey, C, Newell, DR, Vormoor, J, Irving, JAE. Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood ALL through upregulation of BIM. Haematologica 2019 104: 1804-1811

Danilenko, M, Hodgson, K, Stones, R, Husain, A, Zangarini, M, Veal, G, Rajan, N. Diverse assays from a single skin punch biopsy to assess topical drug intervention. Br J Dermatology 2019 180: 937-938

Chen, L, Pastorino, F, Berry, P, Bonner, J, Kirk, C, Wood, KM, Thomas, HD, Zhao, Y, Daga, A, Veal, GJ, Lunec, J, Newell, DR, Ponzoni, M, Tweddle, DA. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Int J Cancer 2019 144: 3146-3159

Duong, JK, Veal, GJ, Nath, CE, Shaw, PJ, Errington, J, Ladenstein, R, Boddy, AV. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: A re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Br J Clin Pharmacol 2019 85: 136-146

Brock, PR, Maibach, R, Childs, M, Rajput, K, Roebuck, D, Sullivan, MJ, Laithier, V, Ronghe, M, dall'Igna, P, Hiyama, E, Brichard, B, Skeen, J, Mateos, ME, Capra, M, Rangaswami, AA, Veal, GJ, Brugières, L, Perilongo, G, Czauderna, P, Morland, B, Neuwelt, EA. Sodium thiosulfate for protection from cisplatin-induced hearing loss. New Engl J Med 2018 378: 2376-2385

Martinez-Soria, N, McKenzie, L, Draper, J, Ptasinska, A, Issa, H, Potluri, S, Blair, HJ, Pickin, A, Isa, A, Tirtakusuma, R, Coleman, D, Pal, D, Nakjang, S, Suyin Chin, P, Assi, S, Forster, V, Reza, M, Law, E, Berry, P, Mueller, D, Elder, A, Veal, GJ, Cockerill, PN, Wichmann, C, Vormoor, J, Lacaud, G, Bonifer, C, Heidenreich, O. The oncogenic transcription factor RUNX1/ETO corrupts cell cycle regulation to drive leukemic transformation. Cancer Cell 2018 34: 626-642

Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GJ, Allan JM. Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances 2018 2:1157-1169.

Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL. Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? British Journal of Cancer 2018 118:248-257

Danilenko, M, Stamp, E, Stocken, DD, Husain, A, Zangarini, M, Cranston, A, Stones, R, Sinclair, N, Hodgson, K, Bowett, SA, Roblin, D, Traversa, S, Plummer, R, Veal, G, Langtry, JAA, Ashworth, A, Burn, J, Rajan, N. Efficacy of targeting tropomyosin receptor kinase in cutaneous CYLD defective tumours (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib. JAMA Dermatology 2018 154: 913-921

Thomas, F, Veal, GJ, El Balkhi, S, Lafont, T, Picard, N, Brugières, L, Chatelut, E, Piguet, C. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemother Pharmacol 2018 82: 361-365

White-Koning, M, Osborne, C, Paci, A, Boddy, AVB, Chatelut, E, Veal, GJ. Investigating the potential impact of dose-banding for systemic anti-cancer therapy (SACT) in the paediatric setting based on pharmacokinetic evidence. Eur J Cancer 2018 91: 56-67

Kim, HY, Veal, GJ, Zhou, F, Boddy, AV. The Role of Solute Carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients. Eur J Clin Pharmacol 2018 74: 1575-1584

Fischer-Huchzermeyer S, Chikobava L, Stahn V, Zangarini M, Berry P, Veal GJ, Senner V, Mautner VF, Harder A. Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. BMC Research Notes 2018 11:520

Seddon, B, Strauss, SJ, Whelan, J, Leahy, M, Woll, PJ, Cowie, F, Rothermundt, C, Wood, Z, Benson, C, Ali, N, Marples, M, Veal, GJ, Jamieson, D, Küver, K, Tirabosco, R, Forsyth, S, Nash, S, Dehbi, H-M, Beare, S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017 18: 1397-1410

Veal, GJ, Malik, S, Lupo, M, MacFarlane, S, Lepola, P, Costello, M, Ceci, A, Boué, C, Lecour, L, Otto, A, Rastegari, M, Berry, P. Investigating the roles and training of paediatric research nurses working across Europe - a questionnaire-based survey. BMJ Paediatrics Open 2017 1: e00170 1-7

Zangarini, M, Berry, P, Sludden, J, Raynaud, FI, Banerji, U, Jones, P, Edwards, E, Veal, GJ. Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 (CHK1) inhibitor SRA737 in human plasma. Bioanalysis 2017 9: 1001-1010

Vormoor, B, Veal, GJ, Griffin, MJ, Boddy, AV, Irving, J, Minto, L, Case, M, Banerji, U, Swales, KE, Tall, JR, Moore, AS, Toguchi, M, Acton, G, Dyer, K, Schwab, C, Harrison, CJ, Grainger, JD, Lancaster, D, Kearns, P, Hargrave, D, Vormoor, J. A Phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukaemia: challenges to run early phase clinical trials for children with leukaemia. Ped Blood Cancer 2017 64: e26351 1-4

Jamieson D, Sunter N, Muro S, Pouché L, Cresti N, Lee J, Sludden J, Griffin MJ, Allan JM, Verrill MW, Boddy AV. Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide. Eur J Cancer 2017 71:15-24.

Ribeiro R, Pal D, Jamieson D, Rankin K, Benning M, Dalgarno K, Ferreira A. Temporary Single Cell Coating for Bioprocessing via a Cationic Polymer. ACS Applied Materials & Interfaces 2017 9:12967-12974.